NCBI PubMed Central
open access
Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Licensing Life-Saving Drugs for Developing Countries: Evidence from the Medicines Patent Pool#667364
- Determining the return on investment of a global adaptive platform trial for critically ill patients during COVID-19: A value of implementation analysis in low- and middle-income countries and globally#445489
- Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade.#481003
- Stakeholder-reported perspectives on decentralized clinical trials: A multi-country descriptive survey.#1329762
- Exploring Regulatory Flexibility to Create Novel Incentives to Optimize Drug Discovery#87697
Record · ID 1251972
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive